New Drug Dossier - Medical Marketing and Media

MM&M's New Drug Dossier combines promotional insights with clinical information to offer marketers the first complete online resource for newly approved drugs. Each dossier features agency rosters, marketing strategy, recent news coverage, clinical insights from Monthly Prescribing Reference (MPR), market data from IMS Health, physician outlook from the GfK US Healthcare Companies and late-stage pipeline candidates from Adis R&D Insight.

For more information or to subscribe click here »

SAMPLE DOSSIER: Vyvanse

November 21, 2007

Shire's marketing strategy with Vyvanse involves converting patients from category leader Adderall XR over to the new drug, which launched in June after its February approval to treat symptoms of ADHD in children aged 6 to 12.

FULL DRUG INDEX

Adcirca

Afinitor

Afluria

Akten

Altabax

Alvesco

Angeliq

Arcalyst

Arzerra

Azasite

Azor

Banzel

Brovana

Bystolic

Calomist

Cimzia

Cleviprex

Combigan

Divigel

Doribax

Effient

Elestrin

Endometrin

Entereg

Epiduo Gel

Evamist

Exforge 5/160

Fanapt

Feraheme

Fexmid

Flector Patch

Fosteum

Fusilev

Ibudone

Implanon

Intelence

Invega

Invega Sustenna

Isentress

Istodax

Ixempra

Ixiaro

Janumet

Kapidex

Kinrix

Kuvan

Lexiscan

Lialda

Liquadd

Livalo

Lusedra

Lybrel

Moxatag

Multaq

Neupro

Nplate

Omnaris

Onglyza

Ozurdex

Pataday

Patanase

PegIntron/REBETOL

Pentacel

Perforomist

PrandiMet

Pristiq

Prolia

Promacta

Pylera

Reclast

Recothrom

Relistor

Renvela

RiaSTAP

Rotarix

Samsca

Saphris

Savella

Selzentry

Simcor

Simponi

Symbicort 160/4.5

Symbyax

Tasigna

Tekturna

Tekturna HCT

Torisel

Totect

Toviaz

Treanda

Treximet

Triesence

TriLipix

Tykerb

Tyvaso

Tyzeka

Uloric

Valcyte

Vectical Ointment

Veramyst

Most Recent Approvals

Victoza

August 04, 2010

Novo Nordisk is supporting the launch of Victoza with an aggressive marketing campaign that stresses its ability to do more than reduce blood-sugar levels.

Prolia

June 25, 2010

Amgen is positioning this biologic as fulfilling a significant clinical need in the management of women with postmenopausal osteoporosis (PMO) who are at high risk for fractures.

VPRIV

June 02, 2010

Before the FDA approved VPRIV (velaglucerase alfa) in February, Gaucher patients had access on a preapproval basis, and access figures as one plank in an aggressive launch strategy designed to exploit vulnerabilities in the market.

Afinitor

June 02, 2010

Afinitor, the latest anti-cancer med to spring from Novartis' bustling oncology franchise, launched to professionals in the first half of 2009.

Xiaflex

April 09, 2010

Auxilium launched Xiaflex about a month after US approval through a team of about 100 field sales managers and reps, reimbursement specialists and managed market account directors, plus 11 MSLs providing medical support.

Fanapt

April 07, 2010

Novartis' brand-new psychiatry field force began detailing Fanapt to specialists in January 2010, a mere two months following completion of its North American marketing deal with developer Vanda.

Arzerra

February 22, 2010

Arzerra (ofatumumab) is approved for patients with chronic lymphocytic leukemia (CLL) whose cancer is no longer being controlled by other forms of chemotherapy. The product was approved under the FDA's accelerated approval process, which allows earlier approval of drugs that meet unmet medical needs.

Istodax

February 12, 2010

Istodax won US clearance in November for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior therapy. Gloucester has anticipated seeking approval next year for Istodax for peripheral T-cell lymphoma (PTCL), a larger market.

Zenpep

September 30, 2009

Delayed-release capsules for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions. Zenpep is the only FDA-approved pancreatic enzyme product (PEP) that has been evaluated in clinical studies in adults and children—including children from one to 12 years old—and will offer four dosage strengths to meet the varied needs of infants, toddlers, adolescents and adults with EPI.

Saphris

September 30, 2009

Acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults.